Assessment and management of cardiovascular disease in patients with chronic kidney disease

**ABSTRACT**

The present letter to the editor compares the difficulties concerning the assessment and management of cardiovascular disease in children and adolescents with chronic kidney disease with those found in adult patients.

**Keywords:** chronic kidney failure, child health (public health), child mortality, atherosclerosis.


**DEAR EDITOR,**

It was with great interest that I read the article *Assessment and management of cardiovascular disease in patients with chronic kidney disease* by Bucharles SGE, Varela AM, Barberato SH, and Pecoits-Filho R. The authors reported the risk factors, methods of assessment, and clinical management of cardiovascular disease (CVD) in adults with chronic kidney disease (CKD). It is worth emphasizing some particularities of the pediatric population affected by CKD.

Cardiovascular disease is known to be the second cause of mortality in children with end-stage CKD.\(^1,2\) Data from NAPRTCS indicate that the mortality of children starting replacement renal therapy (RRT) is inversely proportional to the age of RRT onset, “cardiopulmonary” being the most common cause of mortality.\(^3\)

Having this in mind, how should the “cardiovascular health” of children with CKD be assessed?

Mortality of cardiovascular etiology in the pediatric population with stage V CKD is approximately 40%, representing a 700%-increase in mortality as compared with that of the general population (healthy children of the same age bracket).

Endothelial dysfunction occurs early in children with CKD and is followed by calcification of the tunica media, and later left ventricular hypertrophy. Elevations in the levels of systolic blood pressure and intact PTH, calcium and phosphorus, in addition to long periods on dialysis, seem to be important risk factors for CVD in that population.\(^4,5\) The atherosclerotic process starts in childhood and, even when subclinical, can be assessed by use of the carotid intima-media thickness measurement. That method, however, is not widely available in Brazil and, depending on the patient’s age, poses technical difficulties.

Another hindrance is the treatment of dyslipidemia. The lipid levels recommended for children and adolescents are lower than those for adults. Sometimes adequate lipid level control cannot be achieved only with the nutritional approach, requiring the use of lipid-lowering drugs. However, the printed instructions of statins available in Brazil reads “the safety and efficacy of statins for children have not yet been established”, which is a frequent cause of questioning by parents, adding one more difficulty to that approach.

One more factor related to the growth deficiency in children with CKD is that, despite the innumerous publications showing the good response to the use of somatotropin, the state secretariats of health have not included the use of that hormone for CKD patients in its list of recommendations.

In addition to the above-cited difficulties faced by pediatric nephrologists, it is worth noting the social difficulties as determinants of greater challenges in the treatment of children with CKD as compared with that of adults.
REFERENCES


